Resolution of Oral Bisphosphonate and Steroid-Related Osteonecrosis of the Jaw-A Serial Case Analysis

Journal of Oral and Maxillofacial Surgery

Volumn 68, Issue 5, 2010, Pages 1055-1063

  Chiu, Chang Ta ^a   Chiang, Wei Fan ^b   Chuang, Ching Ya ^c   Chang, Sung Wen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c TAINAN SIN LAU HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; LEVOFLOXACIN; MEDRONATE TECHNETIUM TC 99M; PENICILLIN V POTASSIUM; STEROID;

ACTINOMYCOSIS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE BIOPSY; BONE METABOLISM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DEBRIDEMENT; DISEASE SEVERITY; FISTULA; HISTOPATHOLOGY; HUMAN; HYPERBARIC OXYGEN; JAW OSTEONECROSIS; LONG TERM CARE; OSTEOPOROSIS; PRACTICE GUIDELINE; QUALITY OF LIFE; RADIODIAGNOSIS; REMISSION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCINTIGRAPHY; STEROID THERAPY; TAIWAN; TREATMENT DURATION;

ACTINOMYCOSIS; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; ANTI-BACTERIAL AGENTS; BONE DENSITY CONSERVATION AGENTS; DEBRIDEMENT; DIPHOSPHONATES; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; HYPERBARIC OXYGENATION; JAW DISEASES; MANDIBULAR DISEASES; MAXILLARY DISEASES; MIDDLE AGED; OSTEOLYSIS; OSTEONECROSIS; OSTEOSCLEROSIS; RISK FACTORS; TAIWAN; TREATMENT OUTCOME;

EID: 77950839927     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2009.12.030     Document Type: Article

References (32)

1. Zein C.O., Jorgensen R.A., Clarke B., et al. Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial. J Hepatol 42 (2005) 762
2. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189
3. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
4. Fischer B.A., Mundle S., and Cole A.A. Tumor necrosis factor-alpha induced DNA cleavage in human chondrocytes may involve multiple endonucleolytic activities during apoptosis. Microsc Res Tech 50 (2000) 236
5. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 63 (2005) 1567
6. Hellstein J.W., and Marek C. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682
7. Van Beek E.r., Löwik C.W.G.M., and Papapoulous S.E. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen containing bisphosphonates on osteoclast precursors. Bone 30 (2002) 64
8. Sawatari Y., and Marx R.E. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am 19 (2007) 487
9. Cafro A.M., Barbarano L.A., Andriani A., et al. Osteonecrosis of the jaw associated with chronic bisphosphonates therapy: An Italian experience. Blood (American Society of Hematology, Annual meeting abstracts) 106 (2005) 5152
10. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
11. Joan C.L., and Oakland C.A. Risks associated with oral bisphosphonates. J Oral Maxillofac Surg 67 suppl 1 (2009) 3
12. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23 (2005) 8580
13. Product information (Fosamax) (2005), Merck Co, Whitehouse Station, NJ
14. Lasseter K.C., Porras A.G., Denker A., et al. Pharmacokinetic considerations in determining the terminal elimination half lives of bisphosphonates. Clin Drug Invest 25 (2005) 107
15. American Dental Association: Report of the Council of Scientific Affairs. Expert panel recommendations: Dental management of patients on oral bisphosphonate therapy June 2006. http://www.ada.org/prof/resources/topics Accessed June 29, 2006
16. Pozzi S., Marcheselli R., Sacchi S., et al. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. Blood (American Society of Hematology, Annual meeting abstracts) 106 (2005) 5057
17. Zavras A.I., and Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis?. J Oral Maxillofac Surg 64 (2006) 917
18. Chen P.Q. The current strategy on the prevention and treatment of osteoporosis in Taiwan. J Bone Miner Metab 20 (2002) 131
19. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24 (2006) 945
20. Ruggiero S.L., Fantasia J., and Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 (2006) 433
21. Allen M.R., and Burr D.B. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66 (2008) 987
22. Brunski J.B. In vivo bone response to biochemical loading at the bone/dental-implant interface. Adv Dent Res 13 (1999) 99
23. Marx R.E., Cillo J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. Oral Maxillofac Surg 65 (2007) 2397
24. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753
25. Carter G., Goss A.N., and Doecke C. Bisphosphonates and avascular necrosis of the jaw: A possible association. Med J Aust 182 (2005) 413
26. Harper R.P., and Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: Possible application for intermittent low-dose parathyroid hormone [rhPTH(1 to 34)]. J Oral Maxillofac Surg 65 (2007) 573
27. Marx R.E. Chronic osteomyelitis of the jaws. Oral Maxillofacial Clin North Am 3 (1991) 367
28. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538
29. Santini D., Vincenzi B., Avvisati G., et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8 (2002) 1080
30. Niinikoski J. Cellular and nutritional interactions in healing wounds. Med Biol 58 (1980) 303
31. Marx R., and Johanson R. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol 64 (1987) 379
32. Annane D., Depondt J., Aubert P., et al. Hyperbaric oxygen therapy for radionecrosis of the jaw: A randomized, placebo-controlled, double-blind trial from the ORN96 study group. J Clin Oncol 22 (2004) 4893